Zongqi Xia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7899126/publications.pdf

Version: 2024-02-01

53	2,151	331538	254106
papers	citations	21	43
		h-index	g-index

69	69	69	3582
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of phenotype algorithms using electronic medical records and incorporating natural language processing. BMJ, The, 2015, 350, h1885-h1885.	3.0	226
2	Normalization of Plasma 25-Hydroxy Vitamin D Is Associated with Reduced Risk of Surgery in Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2013, 19, 1.	0.9	168
3	A Direct Interaction of PSD-95 with 5-HT2A Serotonin Receptors Regulates Receptor Trafficking and Signal Transduction. Journal of Biological Chemistry, 2003, 278, 21901-21908.	1.6	152
4	Improving Case Definition of CrohnÊ¼s Disease and Ulcerative Colitis in Electronic Medical Records Using Natural Language Processing. Inflammatory Bowel Diseases, 2013, 19, 1411-1420.	0.9	142
5	Psychiatric coâ€morbidity is associated with increased risk of surgery in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2013, 37, 445-454.	1.9	101
6	Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States. Journal of the American Academy of Dermatology, 2008, 59, 582-588.	0.6	99
7	High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP). Nature Protocols, 2019, 14, 3426-3444.	5.5	94
8	Methods to Develop an Electronic Medical Record Phenotype Algorithm to Compare the Risk of Coronary Artery Disease across 3 Chronic Disease Cohorts. PLoS ONE, 2015, 10, e0136651.	1.1	82
9	Similar Risk of Depression and Anxiety Following Surgery or Hospitalization for Crohn's Disease and Ulcerative Colitis. American Journal of Gastroenterology, 2013, 108, 594-601.	0.2	72
10	The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience, 2003, 122, 907-920.	1.1	71
11	Modeling Disease Severity in Multiple Sclerosis Using Electronic Health Records. PLoS ONE, 2013, 8, e78927.	1.1	67
12	Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members. JAMA Neurology, 2017, 74, 293.	4.5	46
13	Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Annals of Neurology, 2016, 79, 178-189.	2.8	45
14	A scalable online tool for quantitative social network assessment reveals potentially modifiable social environmental risks. Nature Communications, 2018, 9, 3930.	5.8	37
15	Validation of an internationally derived patient severity phenotype to support COVID-19 analytics from electronic health record data. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1411-1420.	2.2	37
16	International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. JAMA Network Open, 2021, 4, e2112596.	2.8	33
17	Distinguishing Admissions Specifically for COVID-19 From Incidental SARS-CoV-2 Admissions: National Retrospective Electronic Health Record Study. Journal of Medical Internet Research, 2022, 24, e37931.	2.1	33
18	Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology, 2013, 81, 1891-1899.	1.5	32

#	Article	IF	Citations
19	Common variation near IRF6 is associated with IFN-Î²-induced liver injury in multiple sclerosis. Nature Genetics, 2018, 50, 1081-1085.	9.4	32
20	Inpatient Mortality in Children With Clinically Diagnosed Malaria As Compared With Microscopically Confirmed Malaria. Pediatric Infectious Disease Journal, 2008, 27, 319-324.	1.1	29
21	Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity. Multiple Sclerosis and Related Disorders, 2016, 8, 136-140.	0.9	29
22	Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Multiple Sclerosis and Related Disorders, 2022, 57, 103433.	0.9	26
23	A 17q12 Allele Is Associated with Altered NK Cell Subsets and Function. Journal of Immunology, 2012, 188, 3315-3322.	0.4	24
24	Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 366-379.	1.4	24
25	Molecular and Cellular Mechanisms for the Polarized Sorting of Serotonin Receptors: Relevance for Genesis and Treatment of Psychosis. Critical Reviews in Neurobiology, 2004, 16, 229-236.	3.3	23
26	Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis. JAMA Network Open, 2021, 4, e2134627.	2.8	23
27	Association of social network structure and physical function in patients with multiple sclerosis. Neurology, 2020, 95, e1565-e1574.	1.5	21
28	Manifestations and impact of the COVIDâ€19 pandemic in neuroinflammatory diseases. Annals of Clinical and Translational Neurology, 2021, 8, 918-928.	1.7	21
29	A Putative Alzheimer's Disease Risk Allele in PCK1 Influences Brain Atrophy in Multiple Sclerosis. PLoS ONE, 2010, 5, e14169.	1.1	20
30	Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology, 2017, 88, 677-684.	1.5	20
31	Hypertrophic pachymeningitis and cerebral venous sinus thrombosis in inflammatory bowel disease. Journal of Clinical Neuroscience, 2010, 17, 1454-1456.	0.8	19
32	Leveraging electronic health records data to predict multiple sclerosis disease activity. Annals of Clinical and Translational Neurology, 2021, 8, 800-810.	1.7	19
33	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study. Journal of Medical Internet Research, 2021, 23, e31400.	2.1	19
34	Steroid Responsive A3243G Mutation MELAS. Neurologist, 2012, 18, 159-170.	0.4	18
35	Complex relation of HLA-DRB1*1501 , age at menarche, and age at multiple sclerosis onset. Neurology: Genetics, 2016, 2, e88.	0.9	17
36	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	17

#	Article	IF	Citations
37	Automated ICD coding via unsupervised knowledge integration (UNITE). International Journal of Medical Informatics, 2020, 139, 104135.	1.6	17
38	International electronic health record-derived post-acute sequelae profiles of COVID-19 patients. Npj Digital Medicine, 2022, 5, .	5.7	17
39	Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses. Multiple Sclerosis and Related Disorders, 2021, 56, 103229.	0.9	16
40	The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 65, 103994.	0.9	12
41	Paraneoplastic limbic encephalitis presenting as a neurological emergency: a case report. Journal of Medical Case Reports, 2010, 4, 95.	0.4	11
42	Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2022, 58, 103482.	0.9	11
43	Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19. Scientific Reports, 2021, 11, 20238.	1.6	10
44	Minocycline in Multiple Sclerosis â€" Compelling Results but Too Early to Tell. New England Journal of Medicine, 2017, 376, 2191-2193.	13.9	8
45	Predicting Multiple Sclerosis Outcomes During the COVID-19 Stay-at-home Period: Observational Study Using Passively Sensed Behaviors and Digital Phenotyping. JMIR Mental Health, 2022, 9, e38495.	1.7	8
46	Association of personality traits with physical function, cognition, and mood in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 59, 103648.	0.9	7
47	International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality. Npj Digital Medicine, 2022, 5, .	5.7	7
48	Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010â€"2019. Neurology and Therapy, 2022, 11, 1147-1165.	1.4	5
49	Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Multiple Sclerosis and Related Disorders, 2022, 57, 103333.	0.9	4
50	Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2. BMJ Open, 2022, 12, e057725.	0.8	4
51	Mystery Case: A 61-year-old woman with lower extremity paralysis and sensory loss. Neurology, 2017, 89, e257-e263.	1.5	3
52	Gut Microbiome as Potential Therapeutics in Multiple Sclerosis. Current Treatment Options in Neurology, 2021, 23, 1.	0.7	2
53	5-HT Receptor-Associated Proteins (FRAPs). Receptors, 2006, , 257-276.	0.2	0